Rekombinanter TNFSF13B (Tabalumab Biosimilar) Antikörper (AA 133-285)

Produktnummer ABIN7487690

Dieses Kaninchen Chimeric-Antikörper erkennt spezifisch TNFSF13B (Tabalumab Biosimilar) in ELISA, WB, FACS, Func, IF, IP und Neut. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter TNFSF13B (Tabalumab Biosimilar) Antikörper (AA 133-285) (ABIN7487690)

Target: TNFSF13B (Tabalumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser TNFSF13B (Tabalumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA, Western Blotting (WB), Flow Cytometry (FACS), Functional Studies (Func), Immunofluorescence (IF), Immunoprecipitation (IP), Neutralization (Neut)

Produktdetails anti-TNFSF13B (Tabalumab Biosimilar) Antikörper

Bindungsspezifität: AA 133-285

Verwendungszweck: Anti-CD257 (BAFF) [Tabalumab], Rabbit IgG, kappa

Spezifität: Tabalumab neutralises soluble and membrane-bound BAFF, inhibiting BAFF binding to BR3, TACI and BCMA.

Kreuzreaktivität: Cynomolgus, Kaninchen

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG4

Aufreinigung: Protein A affinity purified

Immunogen: Monoclonal antibodies were generated by immunizing human immunoglobulin transgenic mice with soluble human BAFF (amino acids 133-285). Eight mice producing serum antibody titers to human BAFF were injected intravenously with 10 mug human BAFF in phosphate buffered saline. The spleen was harvested 3 days later from each mouse and fused with myeloma cells. 20 Hybridomas were tested for specific binding to human BAFF and to make sure they were expressing human immunoglobulin heavy and light chains by enzyme-linked immunosorbent assay (ELISA). The hybridoma producing the antibody that eventually became tabalumab was a human IgG1 isotype. The antibody was then engineered to a human IgG4 isotype for complete neutralization of BAFF without depletion of BAFF-expressing cells.

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: Tabalumab has been tested in patients with systemic lupus erythematosus (Merrill 2015) and in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (Genovese 2013).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu TNFSF13B (Tabalumab Biosimilar)

Target: TNFSF13B (Tabalumab Biosimilar)

Hintergrund: TNFSF20, B-cell activating factor, Tumor Necrosis Factor Superfamily Member 13b, BAFF, Tumor Necrosis Factor (Ligand) Superfamily, Member 13b, Dendritic Cell-Derived TNF-Like Molecule, TALL-1, TALL1, ZTNF4, BLYS, Tumor Necrosis Factor (Ligand) Superfamily, Member 20, Tumor Necrosis Factor Ligand Superfamily Member 13B, TNF- And APOL-Related Leukocyte Expressed Ligand 1, TNF And ApoL-Related Leukocyte Expressed Ligand 1, Tumor Necrosis Factor-Like Protein ZTNF4, TNF Homolog That Activates Apoptosis, Tumor Necrosis Factor Ligand 7A, ApoL Related Ligand TALL-1, B-Lymphocyte Stimulator, B Lymphocyte Stimulator, CD257 Antigen, Delta4 BAFF, Delta BAFF, TNLG7A, THANK, DTL, LY 2127399, LY2127399

UniProt: Q9Y275